Klinikum Garmisch-Partenkirchen GmbH

The medical center is at the forefront of research in eosinophilic esophagitis, a chronic immune system disease. The focus is on evaluating the long-term safety and tolerability of innovative treatments, such as CC-93538, to improve patient outcomes.

• Long-term safety evaluation
• Immune system modulation
• Chronic disease management

Through its research, the center aims to enhance therapeutic strategies and provide comprehensive care for individuals affected by this condition.

Specializing in hormone receptor positive HER2 negative breast cancer, the center conducts advanced trials to optimize treatment regimens. The MINERVA Trial focuses on the combination of abemaciclib and endocrine therapy, emphasizing digital side effect management to improve patient quality of life.

• Progression-free survival estimation
• Endocrine therapy optimization
• Digital health interventions

By integrating cutting-edge therapies and digital tools, the center is committed to advancing personalized medicine in breast cancer care.

The center is pioneering research in chronic lymphocytic leukemia (CLL), particularly for high-risk patients. The focus is on evaluating the efficacy of a triple combination therapy involving acalabrutinib, obinutuzumab, and venetoclax to extend progression-free survival.

• High-risk CLL management
• Combination therapy efficacy
• Genetic risk factor analysis

Through these efforts, the center aims to transform treatment paradigms and improve prognoses for patients with complex genetic profiles.